In a dramatic turn of events, Sarepta Therapeutics, Inc. finds itself embroiled in a class action lawsuit that could have significant repercussions for its shareholders. The lawsuit, targeting the biotech company, seeks to recover losses for investors who suffered due to alleged securities fraud linked to Sarepta’s gene therapy, ELEVIDYS, between June 22, 2023, and June 24, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The crux of the complaint is that Sarepta allegedly misled investors by downplaying the safety risks associated with ELEVIDYS, a prescription gene therapy for Duchenne muscular dystrophy. The lawsuit claims that the company failed to disclose severe side effects observed during clinical trials, which ultimately led to a halt in recruitment and dosing. This lack of transparency not only attracted regulatory scrutiny but also jeopardized the therapy’s current and future approvals. Investors argue that these omissions painted an overly optimistic picture of the therapy’s potential, thus misleading them.
For those who have invested in Sarepta stock during the specified period, there is an opportunity to seek recovery. Even if you still hold your shares, you can visit the link provided to understand your rights and explore the possibility of participating in the lawsuit. Importantly, joining the class action comes with no cost or obligation.
The legal proceedings are spearheaded by Levi & Korsinsky LLP, a firm with a formidable reputation in securities litigation. With over two decades of experience and a track record of securing substantial settlements for shareholders, Levi & Korsinsky stands as a pillar of support for those seeking justice in complex securities cases.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171